The Oncology Subject Expert Committee (SEC), which is a part of the Central Drugs Standard Control Organisation (CDSCO), has advised that MSN Laboratories Pvt. Ltd. be given the green light to produce and sell Abiraterone Acetate
The U.S. Food and Drug Administration (FDA) has granted final approval to Alembic Pharmaceuticals Limited for its Abbreviated New Drug Application (ANDA) of Sumatriptan Injection which represents a major achievement for the company in the...
Biocon Ltd. informed that its Active Pharmaceutical Ingredient (API) manufacturing facility in Visakhapatnam, Andhra Pradesh
Zydus Lifesciences receives tentative USFDA approval for Olaparib Tablets (100mg, 150mg) used in treating BRCA-related ovarian, breast, pancreatic, and prostate cancers.
Zydus Lifesciences Ltd. is set to broaden its US specialty sector with non-core molecules composition Saroglitazar. The company has a plan to use the funds from its recently approved ?5,000-crore Qualified Institutional Placement
Apollo Hospitals Enterprise Ltd. (AHEL) has demonstrated strong financial performance in the second quarter of FY26 with a 13% year-on-year (YoY) revenue increase to Rs 6,304 crore along with a 26% surge in consolidated profit
Lupin Limited, a global pharmaceutical company, has received the Establishment Inspection Report (EIR) of the Lupin Pithampur Unit-3 plant in Madhya Pradesh. This report is a follow-up to a successful inspection conducted between July 7 and...
Cupid Ltd., a health and wellness products leading manufacturer, revealed that it foresees producing annual revenue of Rs 115 crore from the South African market, after its achievement of securing the largest allocation
Sun Pharmaceutical Industries Ltd has in Q2 of 2026 financial year, to a large extent, sold innovative medicines in the US market than generics. The achievement was a result of a robust market demand for Ilumya
The World Health Organization (WHO) and Bayer AG have renewed their two-decade collaboration to combat neglected tropical diseases (NTDs), extending the partnership through 2025–2030...